GeoVax Labs (NASDAQ:GOVX) is a biotechnology firm focusing on developing vaccines to address infectious diseases, cancers, and for use in immunotherapy. Traded on the NASDAQ stock exchange under the ticker code (NASDAQ:GOVX), the company leverages its unique Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform to produce vaccines that induce robust immune responses. GeoVax's projects span several critical areas, including HIV, COVID-19, Zika virus, hemorrhagic fever viruses, and malaria, alongside working on therapeutic vaccines for chronic Hepatitis B infections and solid tumors. The objective of GeoVax is not only to advance public health through preventive measures against infectious diseases but also to pioneer therapeutic vaccines that could potentially transform cancer treatment paradigms.